Trial Profile
Phase I/II study of S-1, docetaxel, oxaliplatin combination chemotherapy (DOS) in patients with HER2-negative unresectable metastatic gastric cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2018 Results (n=16) assessing safety and efficacy presented at the 2018 Gastrointestinal Cancers Symposium
- 09 Dec 2014 New trial record